Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK, AFFiRiS Enter Alzheimer's Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

GSK, AFFiRiS Enter Alzheimer’s Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline Biologicals (a GSK unit) and AFFiRiS GmbH have entered a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programs that target beta-amyloid. GSK is acquiring exclusive rights to develop and commercialize two vaccine candidates currently in Phase I development that are based on AFFiRiS AFFiTOPE technology. GSK also has an exclusive option to develop and commercialize alternative Alzheimer’s vaccine candidates in preclinical development.
   
Under the terms of the agreement, AFFiRiS will receive an up-front payment of $28.8 million and is eligible for future milestone payments and royalties. The total potential value of the agreement could reach $551.3 million in the event of full commercial success of the candidate vaccines. This agreement is subject to government approval.
   
AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing “rogue” human proteins such as beta-amyloid, which is central to the pathology of Alzheimer’s disease.
   
Walter Schmidt, co-founder and chief executive officer of AFFiRiS, said, “We are pleased that we could secure GSK Biologicals, one of the world’s leading vaccine companies, in collaborating on the development our Alzheimer’s disease vaccine programs. This deal brings together two companies with strong innovation, vaccine development and commercialization capabilities and experience.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters